• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Congenital Hemangiomas: When -- and How -- to Excise (Video: 3:30 minutes)

Article

Congenital hemangiomas that grow rapidly or that threaten a vital organ may now be treated with oral propranol or topical timolol. Details here.

Congenital hemangiomas generally undergo spontaneous resolution; 90% disappear by the time a child reaches age 10. However, removal is indicated if these lesions are growing and/or threatening vital organs.

Treatment options include:
. Oral steroids
. Oral propranolol
. Topical timolol 

Kasabach-Merritt syndrome involves the presence of a large congenital hemangioma that destroys platelets and consumes coagulation factors. These lesions appear in the early postpartum period; affected children often have a bleeding diathesis.
Treatment includes:

. Correcting the coagulopathy

. Addressing the tumor (via surgery, embolization, oral propranolol, oral steroids)      

For more webinar videos, click here.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Scott Ceresnak, MD
Scott Ceresnak, MD
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
© 2024 MJH Life Sciences

All rights reserved.